-+ 0.00%
-+ 0.00%
-+ 0.00%

Core Scientific (CORZ) Could Be 6% Overvalued Following Strong Q3 Earnings

Simply Wall St·11/17/2026 11:18:37
Listen to the news

Why Core Scientific’s Latest Earnings Matter For Investors

Core Scientific (CORZ) just posted third quarter results that showed revenue of US$232.87 million and net income of US$1.18b, compared with revenue of US$81.1 million and a net loss a year earlier.

The earnings release arrived in a mixed price backdrop for Core Scientific, with the share price falling 6.47% on the day to US$13.58 but still up 6.76% over the past week. Even so, the stock’s 90 day share price return is down 27.96% and the 1 year total shareholder return has declined 8.18%. This points to fading momentum despite the stronger quarterly headline numbers.

Scan beyond Core Scientific’s swing to profit and see how other miners and blockchain infrastructure plays stack up in our hand picked 24 cryptocurrency and blockchain stocks.

Core Scientific shares now trade at a steep 50% discount to analyst targets despite the sharp earnings swing into profit. Is the market’s caution sensible, or has pricing moved too far?

Most Popular Narrative: 6% Overvalued

Core Scientific last closed at $13.58 while the most followed narrative on Simply Wall St pegs fair value at $12.76. This frames the stock as slightly expensive on this view and shifts attention toward its Texas data center plans.

According to DanielOliveira, an investor in the Simply Wall St Community, the key debate is less about the recent earnings beat and more about how contracted megawatts in Texas translate into future returns for Core Scientific shareholders.

Core Scientific reported Q3 revenue of $232.9 million against an aggregated consensus of $193.2 million, and adjusted EBITDA of $133.6 million, a 57% margin, up from 25%. Net income of $1.2 billion came from a non-cash gain on warrants, so I would ignore it. The market's concern lies elsewhere, because the beat came from capacity already billing, while the next leg of growth sits in Texas.

See why 2 investors see Core Scientific as 6% overvalued.

Result: Fair Value of $12.76 (OVERVALUED)

Still, the whole Core Scientific story could look very different if ERCOT revisits Texas power allocations or if project timelines slip beyond the current delivery expectations.

Find out about the key risks to this Core Scientific narrative.

Next Steps

If this mix of optimism and caution around Core Scientific feels familiar, that is the point; investors are split and the data is doing the talking. Act while the details are fresh in your mind and weigh both sides for yourself using our breakdown of 1 key reward and 3 important warning signs.

Looking For More Investment Ideas Beyond Core Scientific?

Do not stop at one opportunity. Broaden your watchlist now with a few focused idea sets that can help you pressure test your thesis and spot fresh angles.